Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24857539 | 0.84 | SMN1; SMN2 (0.49) | KMT2AMAPTCYP1A2ALDH1A1PKM | |
| SCHEMBL23029844 | 0.84 | KMT2A (0.42) | KMT2AMAPTGLACYP1A2ALDH1A1 | |
| SCHEMBL24857584 | 0.76 | ALDH1A1 (0.38) | KMT2AMAPTCYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24857397 | 0.74 | KMT2A (0.55) | KMT2AMAPTGLACYP1A2ALDH1A1 | |
| SCHEMBL21893458 | 0.72 | ALDH1A1 (0.40) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL21893930 | 0.72 | F11 (0.35) | KMT2AGLAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL28610782 | 0.71 | ALDH1A1 (0.39) | MAPTALDH1A1SMN1; SMN2 | |
| Potassium Ion SCHEMBL21818390 | 0.70 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| Potassium Ion SCHEMBL21819369 | 0.70 | HTR2A (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL24857777 | 0.69 | GLRA3 (0.36) | KMT2AALDH1A1MEN1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | EZH2, EED, SUZ12 | KMT2A 85/4885MAPT 2522/4885GLA 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.